Actinium Pharma (ATNM) – Press Releases
-
Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Present
-
Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
-
Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand
-
Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transpla
-
Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transp
-
Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
-
Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation
-
Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia
-
Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Expos
-
Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations
-
Actinium Appoints Lynn Bodarky as Chief Business Officer
-
Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023
-
Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable
-
Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy
-
Actinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual Meeting
-
Actinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHO
-
Actinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual Meeting
-
Actinium Pharma Highlights Abstracts Accepted for Oral and Poster Presentation at the EANM 2023 Congress
-
Actinium Pharma to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit
-
SNMMI 2023 Annual Meeting Abstract of the Year Awarded to Actinium's Iomab-B Phase 3 SIERRA Data
-
Actinium Pharma Highlights Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting
-
Actinium Pharma to Present at the Maxim Healthcare Virtual Conference
-
Actinium Pharma to Present at the TD Cowen Radiopharmaceutical Innovation Summit
-
Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results in an Oral Presentation at the EHA 2023 Congress
-
Actinium Pharma Set to Join Russell 2000® and Russell 3000® Indexes
-
Actinium Pharma Announces Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting, Demonstrating Actinium's Leadership in Targeted Radiotherapy for Hematologic and Sol
-
Actinium Pharma Announces Iomab-B SIERRA Trial Results Accepted for Oral Presentation at the European Hematology Association 2023 Congress (EHA)
-
Actinium Pharma to Present at Guggenheim Healthcare Talks Radiopharmaceuticals Day
-
Actinium Highlights Successful Administration of Targeted Radiotherapy Iomab-B Across Various BMT Centers with Ease and Without Increasing Radiation Exposure Risks to Treating Nursing Staff in the Piv
-
Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results of Iomab-B Showcased to the European Transplant Community in Oral Presentation at the European Society for Blood and Marrow Transplanta
-
Actinium Highlights First-In-Class HER3 Targeted Radiotherapy Data Demonstrating Potent Anti-Cancer Activity of in Ovarian and Colorectal Cancer Models at the AACR Annual Meeting
-
Actinium Presents Data Demonstrating Actimab-A's Potential Use Against Solid Tumors by Selectively Depleting Immunosuppressive MDSCs, a Key Component of the Tumor Microenvironment, at the AACR Annual
-
Actinium Pharmaceuticals Reports 2022 Financial Results and Highlights Recent and Upcoming Clinical Data and Milestones
-
Coya Therapeutics Strengthens Leadership Team with Addition of Arun Swaminathan, Ph.D. as Chief Business Officer
-
Actinium to Showcase First-In-Class Targeted Radiotherapies in Two Presentations at the 2023 AACR Annual Meeting
-
Actinium Pharmaceuticals, Inc. to Present at Oppenheimer's 33rd Annual Healthcare Conference
-
Actinium Pharmaceuticals Announces Dr. Sergio Giralt to Discuss Positive Results from the Pivotal Phase 3 SIERRA Trial of Iomab-B via KOL Webinar
-
Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia
-
Actinium to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial on Investor Call Following the Late-Breaker Presentation at the 2023 Transplantation & Cellular Therapy Tandem Meetings o
-
Actinium Signs Cooperative Research and Development Agreement with National Cancer Institute to Further Enhance Clinical and Non-clinical Development of Actimab-A for the Treatment of Acute Myeloid Le
-
Actinium Pharmaceuticals, Inc. to Present at the 3rd Annual B. Riley Securities Oncology Conference
-
Actinium Announces Phase 3 Iomab-B SIERRA Data Accepted for Late-Breaker Presentation at the Transplantation & Cellular Therapy Tandem Meetings
-
Actinium Highlights Survival Data in Relapsed/Refractory AML Patients with Prior Venetoclax Treatment and/or with a TP53 Mutation from the Actimab-A CLAG-M Combination Trial Oral Presentation at ASH
-
Actinium Pharmaceuticals, Inc. Announces Research Collaboration with Columbia University to Study Actimab-A in AML Patients Following Transplant of Engineered Hematopoietic Stem Cells Gene Edited to b
-
Actinium Announces Positive 1-Year and 2-Year Overall Survival Data for Patients with Relapsed or Refractory AML in Phase 1 Actimab-A CLAG-M Combination Trial
-
Actinium Appoints Seasoned Leader Caroline Yarbrough as Chief Commercial Officer to Spearhead Iomab-B Commercialization
-
Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia
-
Actinium Expands Clinical Leadership Team to Support Key Development Programs for Iomab-B and Actimab-A
-
Actinium Pharmaceuticals to Participate in the 2022 Bio-Europe Conference
-
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
Back to ATNM Stock Lookup
